CD19 and cancer: For example, the FDA announced that it begun to investigate the serious risk of secondary cancer following CAR-T treatment at November 28, 2023, and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy at January 24, 2024.